Journal Watch · Nature Communications · 2026

Advanced nanoformulations of NUAK1 regulate NLRP3 inflammasome for preeclampsia management in mice.

This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.

Jiang P, Ying X, Li Z et al.Nature Communications3 min readPharma relevance 60/100

DOI: 10.1038/s41467-026-72775-0PMID: 42151142Study type: preclinical (animal / model) study

TL;DR

This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.

Key findings

  • This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.

What they did

In vitro, these NPs effectively reduced reactive oxygen species levels and suppressed activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, while promoting autophagic activity and inhibiting apoptosis under oxidative stress. In vivo analysis using an L-NAME-induced PE mouse model further confirmed that FLN@(PDA + NUAK1) NPs improved placental structure and fetal growth parameters.

Full abstract (original)

Background: Preeclampsia (PE) is a severe pregnancy complication driven by placental dysfunction and oxidative stress, which currently lacks effective targeted therapies. Here, we evaluated the therapeutic potential of folic acid-modified lipid nanoparticles (NPs) co-loaded with polydopamine and NUAK Family Kinase 1 (NUAK1), termed FLN@(PDA + NUAK1) NPs, for mitigating PE.

What they did: In vitro, these NPs effectively reduced reactive oxygen species levels and suppressed activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, while promoting autophagic activity and inhibiting apoptosis under oxidative stress. In vivo analysis using an L-NAME-induced PE mouse model further confirmed that FLN@(PDA + NUAK1) NPs improved placental structure and fetal growth parameters.

Results & conclusions: This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-72775-0 · PubMed 42151142.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

This study highlights the dual functionality of NPs in activating protective autophagy and suppressing inflammasome overactivation, offering a promising strategy for the treatment of PE.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. In vitro, these NPs effectively reduced reactive oxygen species levels and suppressed activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome, while promoting autophagic activity and inhibiting apoptosis under oxidative stress.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-72775-0. PubMed ID: 42151142. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Jiang P, Ying X, Li Z et al.. Advanced nanoformulations of NUAK1 regulate NLRP3 inflammasome for preeclampsia management in mice.. Nature Communications (2026). DOI: 10.1038/s41467-026-72775-0.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/advanced-nanoformulations-of-nuak1-regulate-nlrp3-inflammasome-for-preec-727750/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides